All News
Filter News
Found 622 articles
-
Study Finds Number of Asthma Biologic Medication Users and Spend Doubled Over 2.5 Years
4/16/2020
New research from Prime Therapeutics LLC (Prime), a pharmacy benefit manager (PBM) serving more than 30 million members nationally, found that among commercially insured members with asthma, the number of members who utilized biologics nearly doubled in a 2.5 year span, as did the amount of spending on those medications.
-
Evelo Biosciences Appoints Neil Graham, M.D., M.B.B.S., M.P.H., as Chief Development Officer Industry veteran brings deep experience in drug development from leadership roles at Regeneron and Vertex
4/15/2020
Evelo Biosciences, Inc. announced the appointment of biopharmaceutical industry veteran Neil Graham, M.D., M.B.B.S., M.P.H., as Chief Development Officer and a member of the Evelo Executive Team.
-
Regeneron and Zai Lab Announce Regional Strategic Collaboration for REGN1979 (CD20xCD3 Bispecific Antibody)
4/8/2020
Zai Lab obtains rights to develop and exclusively commercialize REGN1979 in oncology in mainland China, Hong Kong, Taiwan and Macau
-
Regeneron Finalizes Praluent® (alirocumab) Restructuring and Updates Accounting Presentation
4/6/2020
Company to Report First Quarter 2020 Results and Host Conference Call and Webcast on May 5, 2020
-
Regeneron Announces American College of Cardiology Presentation of Positive Phase 3 Evinacumab Results in Patients with Severe Inherited Form of High Cholesterol
3/30/2020
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced that detailed Phase 3 results of evinacumab were presented today as a late-breaking presentation at the American College of Cardiology's Annual Scientific Session together with World Congress of Cardiology (ACC.20).
-
First patient outside U.S. treated in global Kevzara® (sarilumab) clinical trial program for patients with severe COVID-19
3/30/2020
Phase 2/3 trial initiated in Italy, Spain, Germany, France, Japan, Canada and Russia and is enrolling patients immediately
-
GSK, AstraZeneca, Genentech, and Novartis Identified as the Top Companies Driving Therapeutic Innovation in Asthma
3/18/2020
In an ongoing series of research conducted by KMK Consulting, Inc. covering Innovation & Customer Value, GSK was ranked as the top company delivering superior customer value and sales force engagement, as well as delivering therapeutic innovation in the asthma market according to pulmonary disease specialists.
-
Regeneron Announces Important Advances in Novel COVID-19 Antibody Program
3/17/2020
Regeneron has identified hundreds of virus-neutralizing antibodies; plans to initiate large-scale manufacturing by mid-April with antibody cocktail therapy
-
Sanofi and Regeneron begin global Kevzara® (sarilumab) clinical trial program in patients with severe COVID-19
3/16/2020
* U.S. Phase 2/3 trial initiated and will begin enrolling patients immediately * Regeneron is leading U.S. trials, Sanofi will lead upcoming ex-U.S. trials
-
Regeneron and Sanofi Begin Global Kevzara® (sarilumab) Clinical Trial Program in Patients with Severe COVID-19
3/16/2020
U.S. Phase 2/3 trial initiated and will begin enrolling patients immediately Regeneron is leading U.S. trials, Sanofi will lead upcoming ex-U.S. trials Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced they have started a clinical program evaluating Kevzara ® (sariluma
-
*Achoo* Muddling through a stuffy, runny nose and itchy, watery eyes? You aren’t alone - over 17.6 million American adults (about 7.5%) experience allergic rhinitis (also called hay fever or seasonal allergies). Many different substances (called allergens) can trigger allergic rhinitis, such as ...
-
EYLEA® (aflibercept) Injection Reduced Risk of Developing Vision-Threatening Events by 75% After Two Years in Patients with Diabetic Retinopathy
2/8/2020
New data highlight importance of proactive EYLEA treatment as more than half of untreated patients in PANORAMA developed vision-threatening events over two years
-
It was a busy week for biotech quarterly and annual reports. Here’s a look at some of the top stories including Bristol-Myers Squibb, AbbVie, GSK, Merck and more.
-
Regeneron Reports Fourth Quarter and Full Year 2019 Financial and Operating Results
2/6/2020
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced financial results for the fourth quarter and full year 2019 and provided a business update.
-
Sanofi delivers strong 2019 business EPS growth of 6.8% at CER
2/6/2020
Fourth-quarter 2019 sales performance(3) driven by Dupixent® and Vaccines
-
Regeneron Announces Expanded Collaboration with HHS to Develop Antibody Treatments for New Coronavirus
2/4/2020
TARRYTOWN, N.Y. , Feb. 4, 2020 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced an expanded agreement with the U.S. Department of Health and Human Services (HHS) to develop new treatments combating the novel coronavirus, 2019-nCoV, which was recently declared a global public health emergency by the World Health Organization.
-
The biotech Hotbed known as Pharm Country, which includes New Jersey, Connecticut, New York Pennsylvania and Rhode Island, is an area of rapid growth and change.
-
FDA Accepts for Priority Review Dupixent® (dupilumab) for Children Aged 6 to 11 Years with Moderate-to-Severe Atopic Dermatitis
1/28/2020
If approved, Dupixent would be the first biologic medicine available in the U.S. for these children
-
Here’s a look at the top 10 companies noted in the BioSpace Ideal Employer 2019 survey for being the most innovative and what they’ve been up to recently.
-
Regeneron Announces Encouraging Garetosmab Phase 2 Results in Patients with Ultra-Rare Debilitating Bone Disease
1/9/2020
Approximately 25% decrease in total bone lesions (both new and existing) driven by nearly 90% reduction in formation of new lesions in patients with fibrodysplasia ossificans progressiva (FOP)